

and identification of factors which may be important in disease prevention.

Frequency of response: 5.36 (annual number of responses/annual number of respondents) *Affected public:* Individuals or households. *Types of Respondents:* Individuals recruited for CHS and their selected proxies and physicians. The annual reporting burden is as follows: *Estimated Number of Respondents:* 5,790; *Estimated Number of Responses per respondent:* 5.4; and *Estimated Total Annual Burden Hours Requested:* 8,098. There are no costs for respondents. Estimated annualized cost for information collection for information collection for a 13-year period is \$6,820 thousand per year. This is based on CHS Field, Center and Reading Centers costs in thousands per year. Personnel, \$3,627; Equipment, \$47; Subcontracts, \$257; Other, \$1,437; Overhead, \$1,452. The annualized cost of monitoring the project by the NHLBI is \$207 thousand.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information will have practical utility; (2) The accuracy of the agency's estimate of burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION: To request more information on the proposed project or to obtain a copy of data collection plans and instruments, contact Dr. Robin Boineau, Epidemiology and Biometry Program, Division of Clinical Applications, NHLBI, NIH, II Rockledge Centre, 6701 Rockledge Drive, MSC #7934, Βετηεσδα, MD, 20892-7934, ορ ψαλλ νον-τολλ φρεε νθμβερ (301) 435-0707, ορ Ε-μαιλ νοθρ ρεφθεστ, ινψλθδινγ νοθρ αδδρεσσ το≡ βοινεαθ@νιη.γοω.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received within 60-days of the date of this publication.

Dated: October 1, 1997.

Sheila E. Merritt,

Executive Officer, NHLBI.

[FR Doc. 97-26631 Filed 10-7-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Institutes of Health

Proposed Data Collection: Public Comment; Leukemia and Other Cancers Among Chernobyl Clean-up Workers in Lithuania

SUMMARY: In compliance with the requirement of Section 3506 (c) (2) (A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the National Institutes of Health (NIH), National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

PROPOSED COLLECTION: *Title:* Leukemia and Other Cancers Among Chernobyl Clean-up Workers in Lithuania. *Type of Information Collection Request:* renewal. *Need and Use of Information Collections:* A cohort study will be conducted to investigate the risk of radiation-induced leukemia and other cancers, and of occupationally related cancers, among 7,000 workers from Lithuania who were sent to Chernobyl to clean-up after the accident there in 1986. The workers will be asked to respond to a mail questionnaire or an interview that collects information about specific duties performed during the Chernobyl clean-up, occupational exposures, other cancer risk factors, and incident cancers. The information will be combined with similar information from Estonia and Latvia and used by the National Cancer Institute to determine site-specific risk estimates for cancer based on various exposure patterns.

Frequency of Response: One time; *Affected Public:* Individuals or households; *Type of Respondents:* Chernobyl Workers. The annual reporting burden is as follows: *Estimated Number of Respondents:* 7,000; *Estimated Number of Responses per Respondent:* 1; *Average Burden Hours per Response:* 0.5; and *Estimated Total Annual Burden Hours Requested:* 3,500. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the

public and affected agencies are invited on one or more of the following points: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT:

To request more information on the proposed project or to obtain a copy of the plans and instruments, contact Gilbert W. BeeBe, Ph.D., National Cancer Institute, EPN 400, 6130 Executive Boulevard, Rockville, MD 20892-7364, or call the non-toll-free number (301) 496-5067.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before December 8, 1997.

Dated: September 30, 1997.

Nancie L. Bliss,

OMB Project Clearance Liaison.

[FR Doc. 97-26632 Filed 10-7-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health is seeking licensees for the further development, evaluation, and commercialization of novel progesterone antagonists and pharmaceutical compositions thereof. The invention claimed in U.S. Patent Application 60/016,628 entitled "21-Substituted Progesterone Derivatives As New Antiprogesterone Agents" (HK Kim, RP Blye, PN Rao, JW Cessac, and CK Acosta), filed May 1, 1996, and a related case filed April 30, 1997, are available for either exclusive or non-exclusive licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404).

ADDRESSES: Licensing proposals and questions about this opportunity should be addressed to Ms. Carol Lavrich,

Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7735 ext. 287; fax: 301/402-0220; e-mail: CL21R@NIH.GOV.

Information about the patent applications and pertinent information not yet publicly described can be obtained under a Confidential Disclosure Agreement. Respondees interested in licensing the invention(s) will be required to submit an Application for License to Public Health Service Inventions.

SUPPLEMENTARY INFORMATION: As part of its continuing steroid synthesis program and its expanded mission, the Contraception and Reproductive Health Branch, Center for Population, National Institute of Child Health and Human Development, has developed several 21-substituted derivatives of progesterone for therapeutic applications as antiprogesterational agents.

Preclinical evaluation of these steroids indicates greater antiprogesterational activity and reduced antiglucocorticoid activity compared with mifepristone. These data and those derived from a number of endocrinological, reproductive and receptor binding studies are available for the process of due diligence. None of these data has been published. Radioimmunoassays for these steroids are being developed. No toxicological studies have been undertaken, but extensive safety studies have been performed on a similar antiprogesterational agent.

Antiprogesterational agents have a broad spectrum of potential therapeutic uses in gynecic medicine including cervical ripening, endometriosis, uterine fibroids, breast and endometrial cancer and postmenopausal hormone replacement therapy.

Applicants for licensing are encouraged to submit a research plan which encompasses the most extensive development for therapeutic use.

Dated: September 26, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-26630 Filed 10-7-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: NIAMS SEP Program Project Review.

Date: November 19, 1997.

Time: 8:00 a.m.-5:00 p.m.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Bethesda, Maryland 20815.

Contact Person: Aftab A. Ansari, Ph.D., Scientific Review Administrator, Natcher Building, 45 Center Drive, Rm 5AS25U, Bethesda, Maryland 20892-6500, Telephone: 301-594-4952.

Purpose/Agenda: To evaluate and review research grant applications.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussion of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.846, Project Grants in Arthritis, Musculoskeletal and Skin Diseases Research], National Institutes of Health, HHS)

Dated: October 1, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-26627 Filed 10-7-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Child Health and Human Development Initial Review Group meetings:

Name of Subcommittee: Population Research Subcommittee.

Date: October 9-10, 1997.

Time: October 9-8:00 a.m.-5:00 p.m.; October 10-8:00 a.m.-adjournment.

Place: Bethesda Ramada Hotel, 8400 Wisconsin Avenue, Bethesda, Maryland 20814.

Contact Person: A.T. Gregoire, Ph.D., Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301-496-1485.

Name of Subcommittee: Population Research Subcommittee.

Date: October 16, 1997.

Time: 8:00 a.m.-adjournment.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.

Contact Person: A.T. Gregoire, Ph.D., Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301-496-1485.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Name of Subcommittee: Mental Retardation Subcommittee.

Date: October 20, 1997.

Time: 8:00 a.m.-adjournment.

Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, Maryland 20814.

Contact Person: Norman Chang, Ph.D., Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301-496-1485.

Name of Subcommittee: Maternal and Child Health Research Subcommittee.

Date: October 21-22, 1997.

Time: October 21-8:00 a.m.-5:00 p.m.; October 22-8:00 a.m.-adjournment.

Place: Holiday Inn-Silver Spring, 8777 Georgia Avenue, Silver Spring, Maryland 20910.

Contact Person: Gopal M. Bhatnagar, Ph.D., Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301-496-1485.

Name of Subcommittee: Medical Rehabilitation Research Subcommittee.

Date: October 22-23, 1997.

Time: October 22-8:30 a.m.-5:00 p.m.; October 23-8:30 a.m.-adjournment.

Place: Holiday Inn-Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland.

Contact Person: Ms. Anne Krey, Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301-496-1485.

Purpose/Agenda: To evaluate and review research grant applications.

These meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The discussion of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research for Mothers and Children], National Institutes of Health, HHS)